Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Vectorite Biomedical's Debt-to-EBITDA or its related term are showing as below:
ROCO:4170's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.255 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Vectorite Biomedical Debt-to-EBITDA Related Terms
Vectorite Biomedical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Vectorite Biomedical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4170 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Vectorite Biomedical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectorite Biomedical Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vectorite Biomedical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Vectorite Biomedical (ROCO:4170) has a Debt-to-EBITDA of 0.01 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vectorite Biomedical. According to the industry distribution chart, Vectorite Biomedical ranks #999999 out of 316 companies in the Biotechnology industry.
Is Vectorite Biomedical's Debt-to-EBITDA too high?
Vectorite Biomedical's current Debt-to-EBITDA is 0.01. The Biotechnology industry median Debt-to-EBITDA is 1.26. Vectorite Biomedical's value of 0.01 is 99.2% below this industry median. Based on the distribution chart, Vectorite Biomedical ranks #999999 out of 316 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vectorite Biomedical has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectorite Biomedical ranks #999999 out of 316 companies for Debt-to-EBITDA. This places Vectorite Biomedical in the lower half of its industry. The industry median Debt-to-EBITDA is 1.26. Vectorite Biomedical's value of 0.01 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vectorite Biomedical's current Debt-to-EBITDA of 0.01 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vectorite Biomedical. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vectorite Biomedical's current Debt-to-EBITDA is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Fairly Valued. The stock's GF Value™ is NT$13.89, compared to a current price of NT$12.70 — trading 8.6% below its estimated fair value. The current Debt-to-EBITDA is 0.01 and 99.2% below the Biotechnology industry median of 1.26. Vectorite Biomedical's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current Debt-to-EBITDA is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?
Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued.
The current stock price of NT$12.70 is trading 8.6% below its estimated GF Value™ of NT$13.89.
GuruFocus considers Vectorite Biomedical to be Fairly Valued.
Key valuation signals for ROCO:4170:
Debt-to-EBITDA: 0.01
GF Value™: NT$13.89 vs. price of NT$12.70 (8.6% below fair value)
Industry Position: 99.2% below the Biotechnology median (#999999 of 316)
No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
71GF Score
Get the complete analysis for ROCO:4170
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4170 has been successfully added to your 
